Literature DB >> 11995896

Immune mediated chorea encephalopathy syndrome in childhood.

L M Hartley1, S Y Ng, R C Dale, A J Church, A Martinez, C de Sousa.   

Abstract

We report four previously healthy female children, aged between 3 and 8 years, who presented with encephalopathy and an extrapyramidal movement disorder (chorea n=4, rigidity n=2, oculogyric crisis n=2). In addition, an acute behavioural disturbance occurred in two patients and mutism in two others. Seizures heralded the onset of the illness in three patients. Acute MRI was either normal or initially normal with later generalized cerebral atrophy. All infective (including streptococcus), biochemical, and metabolic investigations were normal, although all four patients had oligoclonal bands in the (CSF) but not the serum, indicating intrathecal immunoglobulin synthesis. All four children made an apparently full recovery within four months of the onset. We suggest that these patients represent an immune-mediated movement disorder and encephalopathy syndrome.

Entities:  

Mesh:

Year:  2002        PMID: 11995896     DOI: 10.1017/s0012162201002055

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  4 in total

Review 1.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

2.  [Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies].

Authors:  J González-Valcárcel; M R Rosenfeld; J Dalmau
Journal:  Neurologia       Date:  2010-09       Impact factor: 3.109

Review 3.  Acute encephalitis and encephalopathy associated with human parvovirus B19 infection in children.

Authors:  Toru Watanabe; Hideshi Kawashima
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 4.  Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome.

Authors:  Mark S Cooper; Vincent P Clark
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-25       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.